In May 2012, the University of California, Berkeley, filed a patent application for biochemist Jennifer Doudna and the University of Vienna’s Emmanuelle Charpentier, then of Umeå University in Sweden, based on their seminal observation that the bacterial CRISPR-Cas9 gene-editing system can be used to target different sequences of DNA by reprogramming the system’s small homing guide RNAs. The Broad Institute of MIT and Harvard followed suit that December with applications for bioengineer Feng Zhang and colleagues covering CRISPR’s use in eukaryotic cells. When the US Patent and Trademark Office (USPTO) granted Zhang’s patent in April 2014, thanks to an expedited review process, a now-infamous dispute was born.

The University of California (UC) group quickly filed for a patent interference hearing, which the USPTO’s Patent Trial and Appeal Board (PTAB) granted in December 2015. In February of this year, however, the PTAB three-judge panel ruled that the Broad’s innovations are patentable separately from the UC team’s original discovery. Not wanting to be limited to gene editing in bacteria, the UC side appealed the ruling in April, claiming that their original application covers the use of this technology in all cells—plant, animal, and human, in addition to bacterial. “There’s a lot of uncertainty right now about who is going to own what rights,” says Lisa Larrimore Ouellette, a law professor at Stanford University.

While the dispute has little bearing on the use of CRISPR-Cas technology by academic researchers—who have unimpeded access so long as they don’t try to sell the fruits of their labor—those hoping to develop this technology for commercial uses find themselves navigating a challenging IP landscape. “[Some companies] have begun to think about licensing from both the Broad and UC Berkley, just to hedge their bets,” says Arti Rai, a law professor and codirector of the Duke Law Center for Innovation Policy at Duke University.

It’s a risky business to be in.—Lisa Larrimore Ouellette, Stanford University

As scientists harness CRISPR for a growing list of medically relevant tasks, including germline editing and CAR T-cell therapy, the stakes continue to rise. “Human therapeutics is where it’s at, commercially,” says bioethicist and former patent attorney Christi Guerrini of Baylor College of Medicine. “That’s the prize.”

Applications constituting more than 1,720 patent families—applications filed for the same invention in multiple countries are considered part of the same patent family—have been submitted worldwide by the Broad, UC, and hundreds of other institutions, companies, and researchers, according to Fabien Palazzoli, an analyst at IPStudies. “Around 100 new patent families on CRISPR are published each month,” says Palazzoli in an email to The Scientist. Less than 10 percent of these patents have been granted thus far, more than one third of them in the U.S., according to Palazzoli. Along with their collective commercial licensees, these patent holders are now making moves that will affect how this technology will be used and who will have access for years to come.

One-stop shop

In April, Denver, Colorado–based MPEG LA, LLC announced the formation of what is known as a patent pool for CRISPR-Cas9 technologies, inviting relevant parties to submit their patented tools to a single consortium that would simplify the licensing process—one license would grant licensees access to the pool’s slew of patents. In theory, the pool would promote access through nonexclusive agreements while still profiting the patent owners through royalty payments. It would especially serve the smaller fish, says MPEG LA’s executive director of biotechnology licensing Kristin Neuman. Licensing every relevant patent can be costly and time-consuming, restricting the number of licenses a smaller company can obtain. This could potentially leave out patent holders with “just one piece of the puzzle,” says Neuman. As part of a pool, however, patent holders “would be able to achieve a broader scope of licensing of their IP rights.”

Claims of granted U.S. patents
Of the patent applications that have been granted, who owns what piece of CRISPR? The gene-editing technology is like an onion: the layers can be peeled back one by one, says Christi Guerrini, a bioethicist at Baylor College of Medicine. In the chart below, multiple patents are listed within the same claim category if they claim different pieces of the same technology. For instance, multiple patents exist for editing and tagging bacteria, though they differ in their precise means. Likewise, the same patent can fall under multiple claim categories, as patents often list more than one claim.
Overarching category Detailed category Examples
System components Endonuclease Cas9, Cas6, Cpf1, split-nexus Cas9-associated polynucleotides, Cas9 nickase, RNA-guided FokI nucleases, mutant Cas9 proteins, chimeric CRISPR enzymes
CRISPR RNA (crRNA)/ trans-activating crRNA (tracrRNA)/guide RNA (gRNA) Extended DNA- and RNA-sensing gRNAs, switchable gRNAs, truncated gRNAs, chimeric gRNAs, DNA-guided CRISPR systems
Vectors Large targeting vectors, viral vectors, plasmid vectors, nanoparticles
Methods and applications Target cell Optimization of CRISPR system for expression and function in eukaryotic and prokaryotic cells
Gene editing uses Correcting genetic mutations in cell lines, producing knock-outs and knock-ins, and regulating transcription
Other methods Processing a target RNA, delivering proteins inside cells
Therapeutics Correcting mutations in proteins associated with Alzheimer’s disease, treatments for cancer cachexia

Already, the Broad, Rockefeller University, Harvard, and MIT have submitted 22 of their granted and pending CRISPR-Cas9 patents for consideration. MPEG LA wouldn’t divulge whether it has successfully wooed other patent holders, but is “very pleased with the results of our call for patents,” Neuman says. Whether UC will join is still unclear. Its decision will likely depend on the outcome of the UC team’s appeal of the patent interference ruling, notes Rai. If UC is granted its broad-reaching patent on appeal, it will command the lion’s share of CRISPR IP, and could likely negotiate for the bulk of the pool’s royalties. But, “historically, the king doesn’t join the pool,” says Rai. “If Berkeley wins, that will create quite a situation.” UC has declined to comment on its plans to enter the pool while the litigation is ongoing.

Regardless of how the situation with UC plays out, these are “early days for the pool,” Neuman stresses, and its key patent holders have yet to define the terms. But, she says, the pool will likely entail nonexclusive licenses, allowing patent holders to enter into agreements with outside parties, should they choose to. It’s hard to predict how the pool would affect existing licensing agreements, she says. “MPEG LA is not privy to such agreements, which are between private parties, so we have no way of knowing how preexisting licenses [would be] affected (if at all) by subsequent patent pool formation,” she writes in an email. As per the pool’s nonexclusive licensing model, patent holders that have entered into exclusivity agreements would be barred from entering the pool with the same exclusively granted patent rights.

Nonexclusive licenses have their pitfalls, notes New York Law School attorney Jacob Sherkow: they don’t lend themselves well to the development of human therapeutics. “You need some form of exclusivity for companies to conduct clinical trials,” he says, as a market monopoly incentivizes companies to take on the costs and liability of developing CRISPR-based treatment for disease. Otherwise, he says, it is unclear if anyone will pony up the resources.

We’re just starting to see what the patent landscape looks like.—Kristin Neuman, MPEG LA

Neuman is familiar with this criticism. “That’s largely why we haven’t seen patent pools operating in human therapy,” she says. But according to her, a patent pool could set the stage for developing CRISPR-based therapeutics. For example, offering foundational CRISPR patents that are not focused on a specific therapy or gene on a nonexclusive basis might stir competition and accelerate innovation by giving “patent owners the opportunity to maximize return and minimize risk on their technology investments from many developers in many fields,” she explains in an email. Narrow, disease-specific patents would be precluded from the patent pool, and thus would allow companies licensing those technologies to maintain exclusivity in a given market.

But Sherkow argues that this strategy doesn’t address the crux of the issue, and is likely to prompt an innovation impasse. “The issue isn’t whether the target-specific patents are available for exclusive licensing,” he writes to The Scientist in an email. “It’s what to do about the foundational patents currently being parceled off in large swaths.”

The technology and scope of the pool’s patents are also still up in the air—this would depend on which patent holders end up joining the pool and the terms they negotiate—although the pool could lay claim to applications in agriculture, industrial biotechnology, and human therapeutics. Depending on how this shakes out, and given the complexity of CRISPR technology, “we might have to do a modular approach” and offer license subsets for specific purposes, Neuman says. The first meeting of the pool’s patent holders is slated for some time between October and the end of the year.

Adding to the uncertainty, vast numbers of CRISPR patent applications are still pending, Neuman adds. “We’re just starting to see what the patent landscape looks like.” Even after it’s formed, the pool will continue to evolve as it keeps up with the ever-changing landscape.

The lay of the land

According to Palazzoli, there are approximately 78 patents with claims pertaining to CRISPR in the U.S. Northeastern universities are in the lead, with 13 inventions affiliated with Zhang’s lab and held by the Broad and its collaborators, including MIT and Harvard, while 14 are held by Harvard and list David Liu and/or George Church as inventors. Although Doudna’s foundational patent is still in dispute, four other patents related to the endoribonuclease Csy4 are affiliated with her lab and held by UC. Of the nonacademic patent holders, Caribou Biosciences, cofounded by Doudna, has seven, while several other companies, including Recombinetics, Regeneron, and Agilent have also carved out their own pieces of CRISPR IP. (See chart at right.)  

CRISPR Patents granted in the U.S.
Currently, according to IPStudies, more than 200 patents have been granted worldwide that cover the components, applications, and delivery of this technology. The U.S. is a leader in this space with almost 80 granted patents with CRISPR claims. The chart below lists some of the major institutions and commercial entities that hold granted US patents with claims to
CRISPR-Cas systems.
Applicant/assignee Granted patents
Agilent Technologies Inc 1
Caribou Biosciences 7
DuPont Nutrition & Health 4
Feldan Bio Inc. 1
Institut Pasteur 1
Larix BioScience LLC 1
Pioneer Hi-Bred International 3
President and Fellows of Harvard College 14
Recombinetics Inc. 1
Regeneron Pharmaceuticals 4
Snipr Technologies Ltd 1
System Biosciences LLC 2
The Broad Institute of MIT and Harvard and collaborators 13
The General Hospital Corporation 3
The Regents of the University of California 4
University of Arkansas for Medical Sciences 1
University of Georgia Research Foundation 3
Vilnius University 1
Most of the patent holders listed above are included based on their claims to CRISPR and/or Cas9 inventions and were identified using the USPTO’s full-text patent database. However, a few that did not explicitly state CRISPR-Cas in their claims were included based on their inventions’ association with or intended use of the CRISPR system.

Inventions that tweak CRISPR’s various molecular components in an effort to optimize the technology shape the patent landscape. In this regard, guide RNAs (gRNAs)—the components of the CRISPR system that lead the Cas9 enzyme to precise locations within target DNA—can be altered to home in on an infinite number of genes and to perform more-selective cuts. Similarly, inventors have made modifications to the Cas9 enzyme or adopted other bacterial endonucleases. Different approaches for modifying eukaryotic cells for the treatment of various diseases can also be separately patentable. (See chart above.)

Earlier this year, Sherkow and University of Utah law professor Jorge Contreras published a detailed snapshot of the CRISPR licensing landscape (Science, 355:698-700). A complete picture, however, is nearly impossible to ascertain due to the lack transparency surrounding licensing. For instance, it’s common for entities to license technology based on pending or unpublished patent applications, says Rai. In fact, it happens all the time, although nothing can be enforced until the patent is granted.

When it comes to commercialization of human therapeutics, it’s clear that the patent holder’s licensees are in control. Both UC Berkeley and the Broad have granted broad, exclusive rights for human therapeutics to their respective commercial enterprises—Berkeley to Caribou Biosciences, Intellia Therapeutics, and CRISPR Therapeutics, and the Broad to Editas Medicine. By granting such far-reaching, unrestrictive licenses, these patent holders have effectively passed off the responsibility of deciding who gets to commercialize CRISPR in the therapeutics space, Sherkow explains, as other entities seeking to commercialize now have to approach these companies for sublicensing. For instance, Editas has an exclusive agreement with Juno for CRISPR-based CAR T-cell technology, whereas CRISPR Therapeutics has granted Vertex rights to use CRISPR for cystic fibrosis therapeutics.

Sherkow argues that this power should be retained by the patent-holding institutions, however, which should grant only narrow and restricted licenses in the first place. This would “maximize competition” and expedite the development of promising products, he says. Under the current model, however, a company with the most appropriate expertise and resources for a particular therapy may be unable to obtain the necessary licenses or sublicenses to pursue it. The lack of oversight on how academic institutions, and their commercial licensees, are dishing up licenses and subsequent sublicenses is concerning, says Larrimore Ouellette. “There is not enough attention being paid to whether research from public institutions, funded by public money, is licensed in a manner that serves public interest.”

Guerrini, on the other hand, feels that the Broad has a thoughtful approach to licensing CRISPR and commends it for negotiating certain restrictions with various commercial entities. For instance, Monsanto holds a nonexclusive license for the use of CRISPR in agriculture, but cannot use the Broad’s technology for commercializing gene drives or tobacco products. Similarly, Editas and its sublicensees cannot venture into germline editing or use CRISPR to grow organs for human transplantation. “Their decisions demonstrate caution and delay where appropriate, and reflect the general ethical consensus on the use of this technology for these purposes,” Guerrini says.

The value of the licenses and sublicenses that have been granted so far remains to be seen, however, pending the outcome of the ongoing legal dispute in the U.S. Some of the license agreements that have enabled the development of CRISPR-based CAR-T treatments, among other therapeutics, stem from the foundational CRISPR patents that are embroiled in the dispute between UC Berkeley and the Broad, for example. Editas, the exclusive licensee of the Broad’s patents that are involved in the dispute, is confident that the PTAB’s no-interference ruling in the Broad’s favor will stand, according to Editas communications head Cristi Barnett. “[T]he appeal does not in any way impact our plans to continue investing in this technology,” she writes in an email to The Scientist.

Regardless, “it’s a risky business to be in,” says Larrimore Ouellette. “[Researchers are] basing their companies on rights that might not end up existing.” 


It’s typical for inventors to apply for the same patent in multiple countries. Overseas, major CRISPR players from the U.S., including the University of California, Berkeley, and the Broad Institute of MIT and Harvard, have done so in order to extend their status as key patent holders. China’s State Intellectual Property Office (SIPO) has granted the UC team its controversial patent with claims to CRISPR in both prokaryotic and eukaryotic cells—the same one that’s embroiled in the dispute with the Broad in the U.S. The European Patent Office (EPO) has also granted UC Berkeley this wide-ranging patent. In Europe, there are currently more than 25 CRISPR-related patents, according to IPStudies, 10 of which belong to the Broad and its collaborators.

This summer, the EPO announced that it will also move forward with granting MilliporeSigma’s CRISPR patent application for the use of the technology in adding genetic information into eukaryotic cells—claims that line up with the Broad and UC Berkeley’s use of CRISPR in eukaryotes, according to patent attorney Catherine Coombes of HGF Limited. This overlap is bound to create uncertainty about who owns what, she notes in an email to The Scientist. “[A] company seeking to utilize CRISPR-Cas9 (e.g. for a particular therapeutic purpose) may ultimately need to seek a license from numerous patent holders in Europe.”